Literature DB >> 22526181

[Intermittent androgen deprivation as therapy for androgen-sensitive prostate cancer. Sense or nonsense?].

P Thelen1, R-H Ringert, H Loertzer, A Strauß.   

Abstract

Androgen deprivation is the predominant therapy for advanced prostate cancer. There is accumulating evidence that phases of intermission in androgen deprivation may have benefits regarding side effects, albeit there is as yet no general recommendation for intermittent androgen deprivation therapy. Recent systematic reviews at least substantiate a benefit from such regimens for general quality of life without therapy compromisation. In addition, preclinical data revealed further potential strategies for intermittent androgen deprivation therapy. Future studies must prove, however, that such approaches can be implemented in the clinical situation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22526181     DOI: 10.1007/s00120-012-2870-1

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  27 in total

1.  Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.

Authors:  S M Harman; E J Metter; J D Tobin; J Pearson; M R Blackman
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

2.  Hormonal Therapy in the Management of Prostate Cancer: An Historical Overview.

Authors: 
Journal:  Mol Urol       Date:  1999

3.  [Problems, objective, and substance of early detection of prostate cancer].

Authors:  C Börgermann; H Loertzer; P Hammerer; P Fornara; M Graefen; H Rübben
Journal:  Urologe A       Date:  2010-02       Impact factor: 0.639

4.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Authors:  Nicolas Mottet; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Hans-Peter Schmid; Theo Van der Kwast; Thomas Wiegel; Filiberto Zattoni; Axel Heidenreich
Journal:  Eur Urol       Date:  2011-01-25       Impact factor: 20.096

Review 5.  Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men.

Authors:  C Cattabiani; S Basaria; G P Ceda; M Luci; A Vignali; F Lauretani; G Valenti; R Volpi; M Maggio
Journal:  J Endocrinol Invest       Date:  2011-11-08       Impact factor: 4.256

6.  Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.

Authors:  Kai-Hsiung Chang; Rui Li; Mahboubeh Papari-Zareei; Lori Watumull; Yan Daniel Zhao; Richard J Auchus; Nima Sharifi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-27       Impact factor: 11.205

7.  Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP.

Authors:  C Y Young; B T Montgomery; P E Andrews; S D Qui; D L Bilhartz; D J Tindall
Journal:  Cancer Res       Date:  1991-07-15       Impact factor: 12.701

Review 8.  Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.

Authors:  Per-Anders Abrahamsson
Journal:  Eur Urol       Date:  2009-08-07       Impact factor: 20.096

9.  Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

Authors:  Fernando E C Calais da Silva; Aldo V Bono; Peter Whelan; Maurizio Brausi; Anton Marques Queimadelos; Jose A Portillo Martin; Ziya Kirkali; Fernando M V Calais da Silva; Chris Robertson
Journal:  Eur Urol       Date:  2009-02-21       Impact factor: 20.096

Review 10.  Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.

Authors:  Chih-Pin Chuu; John M Kokontis; Richard A Hiipakka; Junichi Fukuchi; Hui-Ping Lin; Ching-Yu Lin; Chiech Huo; Liang-Cheng Su
Journal:  J Biomed Sci       Date:  2011-08-23       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.